A role of peroxisome proliferator‐activated receptor γ in non‐alcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Non‐alcoholic fatty liver disease is becoming a major health burden, as prevalence increases and there are no approved treatment options. Thiazolidinediones target the nuclear receptor peroxisome proliferator‐activated receptor γ (PPARγ) and have been investigated in several clinical trials for their potential in treating non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH). PPARγ has specialized roles in distinct tissues and cell types, and although the primary function of PPARγ is in adipose tissue, where the highest expression levels are observed, hepatic expression levels of PPARγ are significantly increased in patients with NAFLD. Thus, NAFLD patients receiving treatment with PPARγ agonists might have a liver response apart from the one in adipose tissue. Owing to the different roles of PPARγ, new treatment strategies include development of compounds harnessing the beneficial effects of PPARγ while restricting PPARγ unwanted effects such as adipogenesis resulting in weight gain. Furthermore, dual or pan agonists targeting two or more of the PPARs have shown promising results in pre‐clinical research and some are currently proceeding to clinical trials. This MiniReview explores adipose‐ and liver‐specific actions of PPARγ, and how this knowledge may contribute in the search for new treatment modalities in NAFLD/NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448 · cited 1×
“By promoting adipose tissue formation, PPARγ paradoxically acts as an insulin sensitizer, even though excess adiposity and obesity is commonly associated with diabetes and insulin resistance.(18) This apparent discrepancy involves the generation of metabolically dysfunctional adipocytes during chronic dyslipidaemia, o…”
BackgroundYamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 1×
“In healthy individuals, DNL only contributes to ~5% of the total intrahepatic triglycerides; however, in NAFLD patients, this number increases to 15%‐23%, indicating an up‐regulation of DNL, and also suggesting that the majority of intrahepatic triglycerides in NAFLD patients originate from reduced secretion and/or in…”
BackgroundPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“An increased formation of adipose tissue is supported by the observed weight gain in TZD‐treated NAFLD patients.(7,9,10) Although patients with NAFLD display increased levels of liver PPARγ, the specific events triggering this up‐regulation during disease progression have not yet been identified.”
BackgroundTranscriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation
Xue, J., Schmidt, S. V., Sander, J., Draffehn, A., Krebs, W., Quester, I., De Nardo, D., Gohel, T. D., Emde, M., Schmidleithner, L., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.01.006 · Cited by 2,210 · cited 1×
“A current view on macrophage polarization is more nuanced and suggests a “spectrum model” encompassing a wider range of activation states, reflecting the many different stimuli and subsequent response characteristics.(50,51) However, for the simplicity of this MiniReview, and in relation to the terminology of the pape…”
BackgroundMacrophage-specific PPARγ controls alternative activation and improves insulin resistance
Odegaard, J. I., Ricardo-Gonzalez, R. R., Goforth, M. H., Morel, C. R., Subramanian, V., Mukundan, L., Eagle, A. R., Vats, D., Brombacher, F., Ferrante, A. W., et al. (2007) · Nature · doi:10.1038/nature05894 · Cited by 2,107 · cited 3×
“In Balb/c mice, bone marrow‐derived macrophage‐specific PPARγ deletion inhibited maturation of M2 macrophages and promoted insulin resistance as well as diet‐induced obesity.(35) Furthermore, CCL4 ‐induced liver injury caused increased hepatic expression of M1 inflammatory cytokines (TNFα and IL‐1β) and exacerbated fi…”
BackgroundObesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085 · cited 5×
“Expression is highest in adipocytes, where PPARγ functions as an inducer of adipocyte differentiation.(14,15) TZDs have significant anti‐diabetic properties in vivo, mediated—at least in part—through increased insulin sensitivity and the selective activation of PPARγ in adipose tissue.”
BackgroundInfluential
Cited by
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
Vujkovic, M., Ramdas, S., Lorenz, K. M., Guo, X., Darlay, R., Cordell, H. J., He, J., Gindin, Y., Chung, C., Myers, R. P., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01078-z · Cited by 205
PFAS and Potential Adverse Effects on Bone and Adipose Tissue through Interactions with PPARγ
Kirk, A. B., Michelsen-Correa, S., Rosen, C., Martin, C. F., & Blumberg, B. (2021) · Endocrinology · doi:10.1210/endocr/bqab194 · Cited by 90
“PPARγ may also play an important role in the development of nonalcoholic fatty liver disease (122).”
BackgroundBartneck, M., Koppe, C., Fech, V., Warzecha, K. T., Kohlhepp, M., Huss, S., Weiskirchen, R., Trautwein, C., Luedde, T., & Tacke, F. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.08.012 · Cited by 44
Yao, Y., Zhang, L., Cheng, F., Jiang, Q., Ye, Y., Ren, Y., He, Y., Su, D., Cheng, L., Shi, G., et al. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03416-2 · Cited by 8
García-Niño, W. R., Zúñiga-Muñoz, A. M., & Maldonado-Macías, X. P. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178715 · Cited by 1
Metadata
- Authors
- Skat‐Rørdam, J., Højland Ipsen, D., Lykkesfeldt, J., & Tveden‐Nyborg, P.
- Venue
- Basic & Clinical Pharmacology & Toxicology
- Publisher
- Wiley
- Published
- 2019-01-22
- Volume
- 124
- Issue
- 5
- Pages
- 528-537
- ISSN
- 1742-7835 (ISSN-L)
- 1742-7843
- OpenAlex
- W2904806538
- Cited by
- 192
- References
- 21
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.